Effects of using vitamins E and C in reducing Extremely Low-Frequency Electromagnetic Fields adverse health effects

Evaluation of Extremely Low Frequency Electromagnetic Fields Effects on Oxidative Stress and Reducing the effects of Oxidative Stress by Intervention of Vitamin E and C in Shaheed Bastami Power Plant’s Workers; A Duble Blind, Randomized Clinical Trial Study

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016020926466N1

Enrollment

Registered

2017-02-28

Start date

2017-06-04

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative stress, DNA damage, Apoptosis, Pre-inflammatory cytokines.

Interventions

Intervention 1: Vitamin E, 400 IU oral tablet, once a day for three months. Intervention 2: Vitamin C, 1000 mg oral tablet, once a day for three months. Intervention 3: Vitamins E and C, 400 IU and 10

Eligibility

Sex/Gender

Male

Age

20 Years to 50 Years

Inclusion criteria

Inclusion criteria: At least one year of experience at the power plant Working full time at the power plant In the range of 20 to 50 years of age

Exclusion criteria

Exclusion criteria: Hypertension according to WHO's definition Using antioxidant dietary supplements Using drugs with antioxidant properties Using vitamins and antioxidants, such as vitamin E, C and beta-carotene and selenium

Design outcomes

Primary

Measure	Time frame
Serum level of malondialdehyde. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of superoxide dismutase. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of catalase. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of glutathione. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of ceruloplasmin. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of total antioxidant capacity. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;DNA damage index. Timepoint: Before and after intervention. Method of measurement: Comet Assay.;Apoptosis. Timepoint: Before and after intervention. Method of measurement: Flow cytometry.;Serum level of interleukin 6. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of interleukin-1 beta. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of tumor necrosis factor alpha. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).	—

Measure

Time frame

Serum level of malondialdehyde. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of superoxide dismutase. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of catalase. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of glutathione. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of ceruloplasmin. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of total antioxidant capacity. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;DNA damage index. Timepoint: Before and after intervention. Method of measurement: Comet Assay.;Apoptosis. Timepoint: Before and after intervention. Method of measurement: Flow cytometry.;Serum level of interleukin 6. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of interleukin-1 beta. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Serum level of tumor necrosis factor alpha. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).

—

Secondary

Measure	Time frame
Cholesterol. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 546 nm wavelength.;Complete blood count. Timepoint: Before and after intervention. Method of measurement: By Cell Counter.;High-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Immunoinhibition.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Direct method.;Alanine transaminase. Timepoint: Before and after intervention. Method of measurement: Colorimetric at 570 nm wavelength.;Aspartate transaminase. Timepoint: Before and after intervention. Method of measurement: Colorimetric at 340 nm wavelength.;Creatinine. Timepoint: Before and after intervention. Method of measurement: Jaffe.;Urea. Timepoint: Before and after intervention. Method of measurement: UV test.;Uric acid. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 520 nm wavelength.;Triglycerides. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 510 nm wavelength.;Glucose. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 546 nm wavelength.;Total protein. Timepoint: Before and after intervention. Method of measurement: Biuret.;Albumin. Timepoint: Before and after intervention. Method of measurement: Bromocresol green.;Vitamin D. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Calcium. Timepoint: Before and after intervention. Method of measurement: Arsenoza.;Phosphorous. Timepoint: Before and after intervention. Method of measurement: U.V test.;High sensitivity C-reactive protein. Timepoint: Before and after intervention. Method of measurement: Immunoturb.	—

Measure

Time frame

Cholesterol. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 546 nm wavelength.;Complete blood count. Timepoint: Before and after intervention. Method of measurement: By Cell Counter.;High-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Immunoinhibition.;Low-density lipoprotein. Timepoint: Before and after intervention. Method of measurement: Direct method.;Alanine transaminase. Timepoint: Before and after intervention. Method of measurement: Colorimetric at 570 nm wavelength.;Aspartate transaminase. Timepoint: Before and after intervention. Method of measurement: Colorimetric at 340 nm wavelength.;Creatinine. Timepoint: Before and after intervention. Method of measurement: Jaffe.;Urea. Timepoint: Before and after intervention. Method of measurement: UV test.;Uric acid. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 520 nm wavelength.;Triglycerides. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 510 nm wavelength.;Glucose. Timepoint: Before and after intervention. Method of measurement: Enzymatic-colorimetric at 546 nm wavelength.;Total protein. Timepoint: Before and after intervention. Method of measurement: Biuret.;Albumin. Timepoint: Before and after intervention. Method of measurement: Bromocresol green.;Vitamin D. Timepoint: Before and after intervention. Method of measurement: Enzyme-linked immunosorbent assay (ELISA).;Calcium. Timepoint: Before and after intervention. Method of measurement: Arsenoza.;Phosphorous. Timepoint: Before and after intervention. Method of measurement: U.V test.;High sensitivity C-reactive protein. Timepoint: Before and after intervention. Method of measurement: Immunoturb.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMajid Bagheri Hossein Abadi

Shahroud University of Medical Sciences

m.bagheri@shmu.ac.ir+98 23 3236 1718

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026